📊 COYA Key Takeaways
Investment Thesis
Coya Therapeutics is a pre-commercial pharmaceutical company burning through cash with severe operating losses and negative margins, though revenue growth of 124% YoY suggests product traction. The company maintains adequate liquidity with $46.8M in cash and minimal debt, but at the current burn rate of $10.7M in operating cash flow losses, runway is limited to approximately 4-5 years without achieving profitability or securing additional financing. Investment viability depends entirely on clinical success and commercialization of pipeline candidates to reverse deeply negative unit economics.
COYA Strengths
- Exceptional revenue growth of 123.6% YoY indicates emerging commercial traction and market adoption
- Strong balance sheet with $46.8M cash, minimal debt (0.00x Debt/Equity), and 8.50x current ratio providing substantial financial flexibility
- Adequate liquidity runway of approximately 4-5 years based on current cash position and operating burn rate
COYA Risks
- Severe operating losses of -$22.6M on only $7.9M revenue with -283.9% operating margin indicate unsustainable unit economics and pre-profitability status
- Negative free cash flow of -$10.7M annually demonstrates the company is not cash generative and remains dependent on capital reserves
- No long-term debt disclosure combined with pharmaceutical sector dynamics suggest future financing needs are likely required before achieving profitability
- Diluted EPS of -$1.27 reflects substantial shareholder dilution, with 9 Form 4 insider filings in 90 days warranting monitoring for capital raising activities
Key Metrics to Watch
- Operating cash flow trend and path to breakeven timeline
- Quarterly revenue growth sustainability and gross margin realization
- Cash balance depletion rate relative to milestone achievements
- Clinical trial progress and regulatory approval status of pipeline candidates
- Insider buying/selling patterns and capital raising announcements
COYA Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 8.50x current ratio provides a solid financial cushion.
COYA Profitability Ratios
COYA vs Healthcare Sector
How Coya Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
COYA Balance Sheet & Liquidity
COYA 5-Year Financial Trend
5-Year Trend Summary: Coya Therapeutics, Inc.'s revenue has grown significantly by 32% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.98 indicates the company is currently unprofitable.
COYA Growth Metrics (YoY)
COYA Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $3.6M | -$2.1M | $-0.13 |
| Q2 2025 | $163.6K | -$2.9M | $-0.19 |
| Q1 2025 | $126.8K | -$5.1M | $-0.35 |
| Q3 2024 | N/A | -$2.7M | $-0.26 |
| Q2 2024 | N/A | -$2.7M | $-0.19 |
| Q1 2024 | N/A | -$2.7M | $-0.28 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
COYA Capital Allocation
COYA SEC Filings
Access official SEC EDGAR filings for Coya Therapeutics, Inc. (CIK: 0001835022)
📋 Recent SEC Filings
❓ Frequently Asked Questions about COYA
What is the AI rating for COYA?
Coya Therapeutics, Inc. (COYA) has an AI rating of SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are COYA's key strengths?
Exceptional revenue growth of 123.6% YoY indicates emerging commercial traction and market adoption. Strong balance sheet with $46.8M cash, minimal debt (0.00x Debt/Equity), and 8.50x current ratio providing substantial financial flexibility.
What are the risks of investing in COYA?
Severe operating losses of -$22.6M on only $7.9M revenue with -283.9% operating margin indicate unsustainable unit economics and pre-profitability status. Negative free cash flow of -$10.7M annually demonstrates the company is not cash generative and remains dependent on capital reserves.
What is COYA's revenue and growth?
Coya Therapeutics, Inc. reported revenue of $7.9M.
Does COYA pay dividends?
Coya Therapeutics, Inc. does not currently pay dividends.
Where can I find COYA SEC filings?
Official SEC filings for Coya Therapeutics, Inc. (CIK: 0001835022) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is COYA's EPS?
Coya Therapeutics, Inc. has a diluted EPS of $-1.27.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.